U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06856278) titled 'Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC' on Feb. 26.
Brief Summary: The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.
Study Start Date: Feb. 22
Study Type: INTERVENTIONAL
Condition:
Anaplastic Throid Carcinoma
Intervention:
DRUG: NKG2D CAR-NK with PD-1 Antibody
Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Zhejiang Provincial People's Hospital
Publis...